Literature DB >> 20880723

Cryoablation vs. radiofrequency ablation for small renal masses.

Ali Pirasteh1, Laura Snyder, Nicholas Boncher, Matthew Passalacqua, David Rosenblum, J David Prologo.   

Abstract

RATIONALE AND
OBJECTIVES: Cancer of the kidney is the third most common cancer of the urinary tract, and renal cell carcinoma is the most lethal of all genitourinary tumors. The incidental discovery of renal cell carcinoma has increased with increased use of cross-sectional imaging. Concomitantly, minimally invasive ablative technologies, including image-guided cryoablation, radiofrequency ablation, and others, have evolved as therapeutic options for small renal masses.
MATERIALS AND METHODS: Between 2006 and 2009, 111 patients (age range, 31-91 years; mean age, 70 years) underwent percutaneous computed tomography-guided thermal ablation for suspected renal cell carcinoma at two major academic centers. Outcomes data were retrospectively collected and analyzed to compare recurrence rates for patients undergoing radiofrequency ablation (n = 41) versus cryoablation (n = 70).
RESULTS: There were four cases of suspicious enhancement on follow-up computed tomography or magnetic resonance imaging in each group, with cumulative imaging recurrence rates of 11% and 7% for radiofrequency ablation and cryoablation, respectively. Log rank test analysis revealed no significant difference between rates of imaging recurrence between the two groups (P = .6044).
CONCLUSIONS: These results suggest that the use of cryoablative technology will result in similar outcomes compared with radiofrequency ablation.
Copyright © 2011 AUR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20880723     DOI: 10.1016/j.acra.2010.08.006

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  15 in total

Review 1.  Update on thermal ablation of renal cell carcinoma: oncologic control, technique comparison, renal function preservation, and new modalities.

Authors:  Ronald J Zagoria; David D Childs
Journal:  Curr Urol Rep       Date:  2012-02       Impact factor: 3.092

2.  Thermoablation of Renal Masses: The Urologist's Perspective.

Authors:  Phillip H Abbosh; Sam B Bhayani
Journal:  Semin Intervent Radiol       Date:  2011-12       Impact factor: 1.513

Review 3.  Renal ablation update.

Authors:  Vishal Khiatani; Robert G Dixon
Journal:  Semin Intervent Radiol       Date:  2014-06       Impact factor: 1.513

Review 4.  Update on cryoablation for treatment of small renal mass: oncologic control, renal function preservation, and rate of complications.

Authors:  Anil Kapoor; Yuding Wang; Brad Dishan; Stephen E Pautler
Journal:  Curr Urol Rep       Date:  2014-04       Impact factor: 3.092

Review 5.  Laparoscopic and image-guided radiofrequency ablation of renal tumors: patient selection and outcomes.

Authors:  Scott M Castle; Vladislav Gorbatiy; Obi Ekwenna; Raymond J Leveillee
Journal:  Curr Urol Rep       Date:  2011-04       Impact factor: 3.092

6.  Salvage Surgery After Percutaneous Ablation of Renal Mass in Solitary Kidney in a Patient With Von Hippel-Lindau.

Authors:  Patrick T Gomella; W Marston Linehan; Mark W Ball
Journal:  Clin Genitourin Cancer       Date:  2019-01-26       Impact factor: 2.872

7.  Percutaneous renal cryoablation complicated by hemorrhage.

Authors:  Jeffrey Critchfield; Joe Harb
Journal:  Semin Intervent Radiol       Date:  2011-06       Impact factor: 1.513

Review 8.  [Ablative therapy of small renal masses].

Authors:  M C Kriegmair; N Wagener; S J Diehl; N Rathmann
Journal:  Urologe A       Date:  2018-03       Impact factor: 0.639

Review 9.  Thermal Ablation of Renal Tumors: Indications, Techniques and Results.

Authors:  Marc Regier; Felix Chun
Journal:  Dtsch Arztebl Int       Date:  2015-06-12       Impact factor: 5.594

Review 10.  [Focal therapy for small renal masses : Observation, ablation or surgery].

Authors:  J J Wendler; B Friebe; D Baumunk; A Blana; T Franiel; R Ganzer; B Hadaschik; T Henkel; K U Köhrmann; J Köllermann; T Kuru; S Machtens; A Roosen; G Salomon; H P Schlemmer; L Sentker; U Witzsch; U B Liehr; J Ricke; M Schostak
Journal:  Urologe A       Date:  2016-05       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.